Posted by Michael Wonder on 19 Apr 2022
Prioritising reference products over biosimilars led to millions of missed savings for Part D
20 April 2022 - Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference product, according to a report from the HHS Office of Inspector General.
Medicare Part D could have saved tens of millions of dollars in 2019 if biosimilars were used at a 60% utilisation rate, according to a report published by the HHS Office of Inspector General.
